OncoMatch/Clinical Trials/NCT06341764
Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma
Is NCT06341764 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for cholangiocarcinoma.
Treatment: Durvalumab 1120 mg · Durvalumab 1500 mg · Tremelimumab i.v. at 300 mg · Cisplatin (CDDP) 25 mg/mq i.v · Gemcitabine (GEM) 1000 mg/mq i.v. — Neoadjuvant chemo- and immunotherapy ameliorate the recurrence rate of cholangiocarcinoma (CCA) at 12 months after surgery.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cholangiocarcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
No previous systemic or local treatments including radiation therapy, radiofrequency ablations, electro-chemotherapy.
Cannot have received: local therapy
No previous systemic or local treatments including radiation therapy, radiofrequency ablations, electro-chemotherapy.
Cannot have received: radiation therapy
No previous systemic or local treatments including radiation therapy, radiofrequency ablations, electro-chemotherapy.
Cannot have received: radiofrequency ablation
No previous systemic or local treatments including radiation therapy, radiofrequency ablations, electro-chemotherapy.
Cannot have received: electro-chemotherapy
No previous systemic or local treatments including radiation therapy, radiofrequency ablations, electro-chemotherapy.
Lab requirements
Blood counts
Haemoglobin ≥9.0 g/dL; ANC ≥1.5 × 10^9/L; Platelet count ≥100 × 10^9/L
Kidney function
Measured or calculated creatinine clearance >40 mL/min
Liver function
Serum bilirubin ≤1.5 x institutional ULN (except Gilbert's syndrome); AST (SGOT)/ALT (SGPT) ≤2.5 x ULN unless liver metastases are present, in which case ≤5x ULN
Adequate normal organ and marrow function as defined below: Haemoglobin ≥9.0 g/dL; ANC ≥1.5 × 10^9 /L; Platelet count ≥100 × 10^9/L; Serum bilirubin ≤1.5 x institutional ULN (except Gilbert's syndrome); AST (SGOT)/ALT (SGPT) ≤2.5 x ULN unless liver metastases are present, in which case ≤5x ULN; Measured or calculated creatinine clearance >40 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify